Watch patient advocate Carol Preston, on location at the 2015 American Society of Hematology (ASH) conference, discusses the new molecule, ACP-196, a second-generation BTK inhibitor, with CLL expert Dr. Kathryn Kolibaba. Dr. Kolibaba describes this new molecules function including its potential for decreased side effects and her hopes for the future. Never, exclaims Dr. Kolibaba, have we had a better menu of options. Never have we had hope like we do now for a cure.
Get email alerts | http://www.patientpower.info/alerts
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo